Prediction market platforms Kalshi and Polymarket launched contracts allowing users to wager on clinical trial outcomes and Food and Drug Administration drug approvals. While proponents argue the markets provide transparent data, researchers and patients condemn the financial incentives as threatening trial integrity and mocking patient suffering.
Prediction markets have rapidly expanded into sports, elections, and global conflicts, and the biopharmaceutical industry is now the latest arena for consumer wagering. Kalshi started taking bets on the outcomes of clinical trials and regulatory reviews in a pilot program launched in partnership with AppliedXL, a firm that monitors and predicts drug development outcomes.
The move brings drug-development odds into public view for the first time, offering contracts tied directly to specific regulatory decisions and late-stage medical studies. Yet the intersection of financial speculation and life-or-death medical research has provoked sharp ethical backlash from clinical researchers, physicians, and families navigating terminal diagnoses.
How the Clinical Trial Prediction Markets Operate
Under the pilot program structure, Kalshi will list a contract only after a trial finishes enrolling, restricting trading exclusively to late-stage studies to mitigate early manipulation risks. Contracts are designed so investors can act on a view regarding a single experimental drug rather than an entire corporate entity.
Photo: statnews.com
Every wager relies on explicit parameters drawn from registered public documentation. AppliedXL helps curate these markets and determine contract settlement criteria using the primary endpoint registered on ClinicalTrials.gov, official FDA approval letters, or the recorded voting records of agency advisory committees.
The initial roster of available contracts includes more than a dozen U.S. Food and Drug Administration decisions. Specific targets at launch include whether regulators will approve Gilead’s experimental cancer drug anito-cel, Summit Therapeutics’ lung cancer drug ivonescimab, and whether an early Alzheimer’s disease treatment developed by AriBio will meet the primary goals of its late-stage trial.
Supporters of prediction markets argue that drug development is one of the most important and most information-constrained industries on earth, where critical data remains locked away behind corporate messaging, according to remarks by Kalshi CEO Tarek Mansour.
Why Prediction Markets like Kalshi & Polymarket are ILLEGAL
Proponents contend that public prediction contracts produce a continuously updated probability reflecting the weight of evidence rather than sponsored spin.
Defenders also point out that financial speculation against pharmaceutical outcomes is hardly novel. Kalshi spokesman Jack Such noted that short sellers in the traditional stock market already profit from clinical trial failures on an order of magnitude larger than prediction exchanges.
“If you want to ban profiting from the failure of clinical trials, you would start with the stock market, where the financial incentive for this type of profit is orders of magnitude larger.”
Platform operators maintain that while both prediction markets and stock trading share financial incentives around failure, prediction exchanges offer the added utility of aggregating probabilistic data for researchers.
Medical Researchers Warn of Trial Tampering and Compromised Integrity
The scientific community remains deeply skeptical of these claims. David Tsai, who runs clinical trials at a San Francisco Bay Area biotech firm, launched an online petition to ban drug trial betting, arguing that wagering on medical studies threatens the very foundation of trust and integrity in biotechnology.
Photo: reuters.com
Researchers emphasize that clinical trials differ fundamentally from political elections or sports matches because insiders can directly manipulate the outcomes being wagered upon.
“If we were running a trial for an oncology drug that requires an infusion, a pharmacist who had placed a bet saying that it’s gonna work well, or doesn’t work well, could obviously adjust the infusion rate, could adjust the source temperature of the drug. They could change any number of variables that could obviously have a direct impact [on] how the trial and the data and the patient safety would come out.”
David Tsai
Human Costs and Patient Family Backlash
For families whose lives intersect directly with experimental treatments, the financialization of medical research carries a profound emotional toll. Joshua Pederson, a humanities professor at Boston University whose 12-year-old son was enrolled in a clinical trial following a cancer recurrence, criticized prediction markets for ignoring the human reality behind the data points.
“What seemed to be missed in the CEO statements was the fact that there were going to be patients on the other side of these bets.”
Exposing the Impossible Odds of Winning on "Prediction Markets" (Polymarket + Kalshi)
Joshua Pederson, Boston University humanities professor
Pederson argued that antiseptic financial terminology masks the devastating physical and emotional consequences of a failed study.
“A clinical trial failing is a more sanitized euphemism for, people are going to suffer, people are going to die, people are going to have one fewer clinical option available to them in one of the most difficult medical situations of their entire life.”
Joshua Pederson, patient’s father
In response to mounting scrutiny regarding insider manipulation, Kalshi implemented safeguards requiring employment verification for all participants and prohibiting trading by individuals with material nonpublic information. Whether these controls can protect vulnerable trials from financial corruption remains a central question as the pilot markets expand.
